9119 Gaither Road
Gaithersburg, MD 20877
United States
301 825 9810
https://www.neximmune.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 6
Nombre | Título | Paga | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Ms. Kristi Jones R.Ph. | CEO, President & Director | 989,28k | N/A | 1963 |
Dr. Mathias Oelke Ph.D. | Chief Scientific Officer | 605,78k | N/A | 1968 |
Mr. John Trainer M.B.A. | Consultant | 1,33M | N/A | 1974 |
Mr. Albert Nicholas Marchio II | Interim CFO & Principal Accounting Officer | N/A | N/A | 1952 |
Mr. Karen Haslbeck | Head of Human Resources | N/A | N/A | N/A |
Dr. Daniel P. Bednarik | Senior Vice President of Molecular Engineering & Protein Design | N/A | N/A | N/A |
Dr. Robert Douglas Knight M.D. | Chief Medical Officer | 454,77k | N/A | 1951 |
Mr. Chad Rubin | Senior Vice President of Corporate Affairs | N/A | N/A | N/A |
Dr. Jack A. Ragheb M.D., Ph.D. | Senior Vice President of Translational Science | N/A | N/A | N/A |
Mr. Matthew Schiller | Head of Business Development | N/A | N/A | N/A |
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. The company was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
El ISS Governance QualityScore de NexImmune, Inc., a día 1 de mayo de 2024, es 10. Las puntuaciones base son Auditoría: 9; Tablero: 8; Derechos de los accionistas: 8; Compensación: 10.